文献速递血液净化与透析水电解质与酸碱

钾结合剂patiromer对血液透析患者血清和粪便电解质的影响

The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis.
PubMed 文献 · Kidney Int · 2020-08-01

本研究在27例无尿的高钾血症血液透析患者中,比较无治疗2周、patiromer(16.8g每日一次)治疗12周及停药6周期间血清和粪便电解质的变化。结果显示治疗期血清钾从5.7 mEq/L降至5.1 mEq/L,停药后回升至5.4 mEq/L;血清钙升高、镁降低,粪便钾和钙升高。提示patiromer治疗期间粪便与血液中钾、钙、镁存在复杂交互。

要点

  • patiromer治疗可降低血透患者血清钾,停药后血钾回升。
  • 治疗期血清钙升高、血清镁降低,需关注电解质变化。
  • 粪便钾增加与血清钾下降相关,提示肠道排钾机制。

核心结论

  • patiromer治疗可降低无尿血液透析患者的血清钾,并升高粪便钾。
  • 治疗期间血清钙升高、血清镁降低,粪便钙升高。

研究设计与样本

  • 自身前后对照研究,纳入27例无尿的高钾血症血液透析患者(主要使用2 mEq/L透析液)。
  • 研究分为无治疗2周、patiromer 16.8g每日一次治疗12周、停药6周三个阶段。

主要发现

  • 血清钾从治疗前均值5.7 mEq/L降至治疗期5.1 mEq/L,停药后回升至5.4 mEq/L。
  • 治疗期血清钙从8.9 mg/dL升至9.1 mg/dL,血清镁从2.6 mg/dL降至2.4 mg/dL。
  • 粪便钾从治疗前4132 μg/g升至治疗期5923 μg/g,停药后降至4246 μg/g。
  • 粪便钙在治疗期为13017 μg/g,高于治疗前7874 μg/g和停药后7635 μg/g。
  • 血清镁每升高1 mEq/L,血清钾升高1.07 mEq/L;粪便钾每升高1 μg/g,血清钾下降0.05 mEq/L。

关键数值与推荐

  • 估计16.8 g patiromer可增加粪便钾1880 μg/g,降低血清钾0.5 mEq/L。

临床怎么用

  • 对血液透析高钾血症患者,patiromer可考虑用于降钾,但需监测血清钙、镁变化。
  • 治疗期间应关注粪便电解质变化所反映的肠道排钾效果。

局限性

  • 样本量小(27例),为自身前后对照,无平行对照组。
  • patiromer长期使用对血清钙、镁影响的后遗效应尚未研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperkalemia is a common and an important cause of death in maintenance hemodialysis patients. Here we investigated the effect of patiromer, a synthetic cation exchanger, to regulate potassium homeostasis. Serum and stool electrolytes were measured in 27 anuric patients with hyperkalemia receiving hemodialysis (mainly 2 mEq/L dialysate) during consecutive two weeks of no-treatment, 12 weeks of treatment with patiromer (16.8g once daily), and six weeks of no treatment. The serum potassium decreased from a mean of 5.7 mEq/L pre-treatment to 5.1 mEq/L during treatment and rebounded to 5.4 mEq/L post-treatment. During the treatment phase, serum calcium significantly increased (from 8.9 to 9.1 mg/dL) and serum magnesium significantly decreased (from 2.6 to 2.4 mg/dL) compared to pre-treatment levels. For each one mEg/L increase in serum magnesium, serum potassium increased by 1.07 mEq/L. Stool potassium significantly increased during treatment phase from pre-treatment levels (4132 to 5923 μg/g) and significantly decreased post-treatment to 4246 μg/g. For each one μg/g increase in stool potassium, serum potassium significantly declined by 0.05 mEq/L. Stool calcium was significantly higher during the treatment phase (13017 μg/g) compared to pre-treatment (7874 μg/g) and post-treatment (7635 μg/g) phases. We estimated that 16.8 g of patiromer will increase fecal potassium by 1880 μg/g and reduce serum potassium by 0.5 mEq/L. Thus, there is a complex interaction between stool and blood potassium, calcium and magnesium during patiromer treatment. Long term consequence of patiromer-induced changes in serum calcium and magnesium remains to be studied.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Amdur RL, Paul R, Barrows ED, et al. The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis. Kidney Int. 2020. PMID: 32750456. doi:10.1016/j.kint.2020.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。